Quantcast
Last updated on April 17, 2014 at 13:30 EDT

Latest Vanda Pharmaceuticals Inc. Stories

2013-05-09 08:29:55

WASHINGTON, May 9, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2013. Key Highlights: On March 25, 2013, Vanda announced that it held a successful Pre-New Drug Application meeting with the U.S. Food and Drug Administration (FDA). The...

2013-04-18 08:30:18

Conference Call and Webcast to Follow WASHINGTON, April 18, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the first quarter of 2013 on Thursday, May 9, 2013, before the market opens. The Company will host a conference call at 10:00 AM ET on Thursday, May 9, 2013, during...

2013-04-17 20:21:27

WASHINGTON, April 17, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), announced today that it has named Paolo Baroldi, M.D., Ph.D. as its Senior Vice President and Chief Medical Officer. Dr. Baroldi has over 30 years of clinical development experience in many therapeutic areas, including neurology and psychiatry. He has been working in the role of acting Chief Medical Officer with Vanda since October 1, 2012. "We welcome Paolo to Vanda and look forward to his...

2013-04-04 20:21:02

Presentation will be Webcast Live and Archived on Vanda's Website WASHINGTON, April 4, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that Jim Kelly, Vanda's Chief Financial Officer, will deliver a corporate presentation at the BioCentury Future Leaders in the Biotech Industry Conference in New York on Friday, April 5, 2013 at 2:30 p.m. Eastern Time. The presentation will be webcast live on Vanda's corporate website, where it also will be...

2013-03-25 08:26:21

WASHINGTON, March 25, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company held a pre-NDA meeting with the Division of Neurology Products of the U.S. Food and Drug Administration (FDA) to discuss the regulatory path for filing a New Drug Application (NDA) for tasimelteon, a circadian regulator, for the treatment of Non-24-Hour Disorder (Non-24). Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind...

2013-03-14 16:28:05

WASHINGTON, March 14, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that it has withdrawn its Marketing Authorization Application (MAA) submitted to the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Fanaptum(TM) (oral iloperidone tablets) for the treatment of adult patients with schizophrenia. This withdrawal is based on a request by the CHMP/Rapporteur/Co-rapporteur for Vanda to submit the results from an...

2013-02-27 20:23:45

Presentation will be Webcast Live and Archived on Vanda's Website WASHINGTON, Feb. 27, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that Mihael Polymeropoulos, M.D., Vanda's President and CEO, will deliver a corporate presentation at the Cowen and Company 33(rd) Annual Health Care Conference in Boston on Monday, March 4, 2013 at 4:50 p.m. Eastern Time. The presentation will be webcast live on Vanda's corporate website, where it also will be...

2013-02-12 08:29:19

WASHINGTON, Feb. 12, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2012. Key Highlights: Vanda reported positive SET and RESET Phase III efficacy studies for tasimelteon in the treatment of patients with...

2013-01-31 08:29:33

WASHINGTON, Jan. 31, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) today announced top-line results of the Phase IIb/III clinical study (MAGELLAN) in Major Depressive Disorder (MDD), investigating the efficacy and safety of tasimelteon as a monotherapy in the treatment of patients with MDD. The clinical study did not meet the primary endpoint of change from baseline in the Hamilton Depression Scale (HAMD-17) after 8 weeks of treatment as compared to placebo. Both...

2013-01-23 08:27:54

WASHINGTON, Jan. 23, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), today announced positive results for the second Phase III study of tasimelteon for the treatment of Non-24-Hour Disorder (Non-24). The RESET study (Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon to treat Non-24-Hour Disorder), demonstrated the maintenance effect of 20mg of tasimelteon to entrain melatonin and cortisol circadian rhythms in individuals with Non-24. Tasimelteon treated...